| Patents for A61K 39 - Medicinal preparations containing antigens or antibodies (182,248) |
|---|
| 02/14/2002 | WO2002012272A2 Therapeutic anti-melanoma compounds |
| 02/14/2002 | WO2002012258A1 New immunoeffector compounds |
| 02/14/2002 | WO2002011767A2 Methods for treating autoimmune and chronic inflammatory conditions using antagonists of cd30 or cd30l |
| 02/14/2002 | WO2002011763A1 Cd40 antagonists for use in treating psoriasis and other inflammatory skin conditions |
| 02/14/2002 | WO2002011761A2 Vaccine against rsv |
| 02/14/2002 | WO2002011760A1 Parenteral vaccine formulations and uses thereof |
| 02/14/2002 | WO2002011759A1 Vaccines against cytokines and growth factors derived from malignant tumours |
| 02/14/2002 | WO2002011758A1 Vaccine against the influenza virus and method for producing said virus vaccine |
| 02/14/2002 | WO2002011757A2 Compositions and methods for inhibiting transmission of malaria |
| 02/14/2002 | WO2002011756A2 Anti-plasmodium compositions and methods of use |
| 02/14/2002 | WO2002011753A1 Protein injection preparations |
| 02/14/2002 | WO2002011748A1 Method and composition for immunization using mixed pools of mutated nucleic acids or peptides |
| 02/14/2002 | WO2002011746A2 Chlorella preparations exhibiting immunomodulating properties |
| 02/14/2002 | WO2002011743A2 Treatment of prostate cancer |
| 02/14/2002 | WO2002011742A2 Methods for preventing reovirus recognition for the treatment of cellular proliferative disorders |
| 02/14/2002 | WO2002011677A2 Treatment of hyperproliferative diseases with epidermal growth factor receptor antagonists |
| 02/14/2002 | WO2002011669A2 Compositions comprising heat shock proteins or alpha(2)macroglobulin, antigenic molecules and saponins, and methods of use thereof |
| 02/14/2002 | WO2002011667A2 Pharmaceutical compositions and methods useful for modulating angiogenesis |
| 02/14/2002 | WO2002011563A1 Food supplement |
| 02/14/2002 | WO2002011540A1 Rotavirus vaccine formulations |
| 02/14/2002 | WO2002005844A8 Protein complex serving as a vehicle for orally administerable medicaments |
| 02/14/2002 | WO2001098471A8 Human phosphodiesterases |
| 02/14/2002 | WO2001081415A9 Parathyroid hormone and parathyroid hormone-related protein antagonists |
| 02/14/2002 | WO2001076531A3 Bile acid containing prodrugs with enhanced bioavailability |
| 02/14/2002 | WO2001075073A3 Prostate cell lines and their use |
| 02/14/2002 | WO2001073080A3 Recombinant iron uptake proteins |
| 02/14/2002 | WO2001070766A3 Therapeutic anti-cytomegalovirus compounds |
| 02/14/2002 | WO2001064874A3 Low density liprotein binding proteins and their use in diagnosing and treating atherosclerosis |
| 02/14/2002 | WO2001064247A3 Method of treating cancer with anti-neurotrophin agents |
| 02/14/2002 | WO2001064243A3 Use of toxoplasma gondii mic3 protein as immunogenic agent |
| 02/14/2002 | WO2001064008A3 Vaccine for the treatment of artherosclerosis |
| 02/14/2002 | WO2001062283A3 Mucosal adjuvant formulation |
| 02/14/2002 | WO2001059093A3 Full-length infectious cdna clones of tick borne flavivirus |
| 02/14/2002 | WO2001058951A3 Water-soluble ligand-binding proteins of ligand-gated ion channels, crystals thereof and their use for screening ligands of ligand-gated ion channels |
| 02/14/2002 | WO2001058922A3 Method and compositions for treating hepatocellular cancer |
| 02/14/2002 | WO2001058915A3 Human g-protein chemokine receptor (ccr5) hdgnr10 |
| 02/14/2002 | WO2001056598A3 Methods for preventing or attenuating pathoangiogenic conditions by using gbs-toxin (cm101) |
| 02/14/2002 | WO2001053463A3 COMPOUNDS AND METHODS FOR PREVENTION AND TREATMENT OF HER-2/neu ASSOCIATED MALIGNANCIES |
| 02/14/2002 | WO2001051619A3 Genetically modified fibroblast cell |
| 02/14/2002 | WO2001049705A3 Method for preparing a polypeptide soluble in an aqueous solvent in the absence of detergent |
| 02/14/2002 | WO2001048161A3 Human heparanase-related polypeptide and nucleic acid |
| 02/14/2002 | WO2001038362A3 Production of vaccines |
| 02/14/2002 | WO2001032695A3 MODULATION OF eNOS ACTIVITY AND THERAPEUTIC USES THEREOF |
| 02/14/2002 | WO2000066143A9 Secreted proteins of mycobacterium tuberculosis and their use as vaccines and diagnostic reagents |
| 02/14/2002 | WO2000065063A9 Nucleic acid vaccines against rickettsial diseases and methods of use |
| 02/14/2002 | WO2000009552A9 Secreted proteins and polynucleotides encoding them |
| 02/14/2002 | WO1995029669A3 Multifunctional ligand for use as a diagnostic or therapeutic pharmaceutical |
| 02/14/2002 | US20020019519 KIAA0551 polynucleotides and polypeptides use |
| 02/14/2002 | US20020019515 Novel spoIIIE |
| 02/14/2002 | US20020019361 Persistent transgene expression, repeated administration of the therapy |
| 02/14/2002 | US20020019358 Compositions and methods for in vivo delivery of polynucleotide-based therapeutics |
| 02/14/2002 | US20020019345 Administering to a patient having implant an effective amount of antagonist of CCR5 (chemokine receptor 5) function, to inhibit graft rejection, antagonist selected from small organic molecules, peptides, proteins, peptidomimetics |
| 02/14/2002 | US20020019343 Antineoplastic conjugates of transferrin, albumin and polyethylene glycol |
| 02/14/2002 | US20020019341 Modulation of systemic memory T cell trafficking |
| 02/14/2002 | US20020019331 Enhancing an immune response to a human self tumor antigen, by immunizing a human being with a foreign protein homologous to human self tumor antigen which is a protein expression product of an overexpressed human oncogene |
| 02/14/2002 | US20020019041 Storing adenoviruses; preparing liquid composition, maintain liquid at freezing, monitor adenovirues for activity |
| 02/14/2002 | US20020018808 Vaccines against sterols |
| 02/14/2002 | US20020018806 Lipopeptide adjuvants |
| 02/14/2002 | US20020018784 Vaccine against mumps containing a jeryl-lynn virus strain |
| 02/14/2002 | US20020018782 Binding to antibodies; prophylaxis, therapy of infections |
| 02/14/2002 | US20020018781 Drugs, vaccines |
| 02/14/2002 | US20020018780 Administering protein, polypeptide containing neutralizing antibodies |
| 02/14/2002 | US20020018779 Non-anaphylactic forms of allergens and their use |
| 02/14/2002 | US20020018778 Passive desensitization |
| 02/14/2002 | US20020018775 Complexing; separation; gene therapy |
| 02/14/2002 | US20020018769 Methods for treating cancers and pathogen infections using antigen-presenting cells loaded with RNA |
| 02/14/2002 | US20020018767 Transformation; gene expression |
| 02/14/2002 | US20020018766 Genes differentially expressed in cancer cells to design cancer vaccines |
| 02/14/2002 | US20020018751 Cellular and serum protein anchors for diagnostic imaging |
| 02/14/2002 | US20020018750 Anticancer agents |
| 02/14/2002 | US20020018749 High avidity polyvalent and polyspecific reagents |
| 02/14/2002 | CA2432423A1 Stabilization of immunogens derived from paramyxoviruses |
| 02/14/2002 | CA2419066A1 Food supplement |
| 02/14/2002 | CA2418939A1 Stabilization of immunogens derived from paramyxoviruses |
| 02/14/2002 | CA2418899A1 Use of immunogens to treat or prevent malignant breast tumours, immune or vascular system disorders stemming from extra-cellular factors |
| 02/14/2002 | CA2418445A1 Stress proteins and peptides and methods of use thereof |
| 02/14/2002 | CA2418353A1 Parenteral vaccine formulations and uses thereof |
| 02/14/2002 | CA2418144A1 Urocortin proteins and uses thereof |
| 02/14/2002 | CA2418091A1 Virus-like particles and process for producing the same |
| 02/14/2002 | CA2418083A1 Treatment of hyperproliferative diseases with epidermal growth factor receptor antagonists |
| 02/14/2002 | CA2418014A1 Immunotherapy for chronic myelocytic leukemia |
| 02/14/2002 | CA2417915A1 Her-2/neu fusion proteins |
| 02/14/2002 | CA2417909A1 Isolation and use of solid tumor stem cells |
| 02/14/2002 | CA2417769A1 Drug metabolizing enzymes |
| 02/14/2002 | CA2417767A1 Peptides presented by cells |
| 02/14/2002 | CA2417368A1 Suppressor gene |
| 02/14/2002 | CA2417357A1 Group b streptococcus polypeptides nucleic acids and therapeutic compositions and vaccines thereof |
| 02/14/2002 | CA2417240A1 Method and composition for immunization using mixed pools of mutated nucleic acids or peptides |
| 02/14/2002 | CA2417214A1 Molecular vaccine linking an endoplasmic reticulum chaperone polypeptide to an antigen |
| 02/14/2002 | CA2416890A1 Therapeutic anti-melanoma compounds |
| 02/14/2002 | CA2406961A1 Cd40 antagonists for use in treating psoriasis and other inflammatory skin conditions |
| 02/13/2002 | EP1179733A1 Compounds and methods for diagnosis of leishmaniasis |
| 02/13/2002 | EP1179541A1 Compositions and methods for cancer treatment by selectively inhibiting VEGF |
| 02/13/2002 | EP1179539A1 Novel protein having hemolytic activity and gene encoding the protein |
| 02/13/2002 | EP1179349A1 W/O emulsion adjuvant compositions for vaccines |
| 02/13/2002 | EP1179348A2 Use of IL-12 and IL-12 antagonists in the treatment of autoimmune diseases |
| 02/13/2002 | EP1179182A2 Diagnosis and treatment of atherosclerosis and coronary heart disease |
| 02/13/2002 | EP1179178A1 Improved method of identifying and locating immunobiologically-active linear peptides |
| 02/13/2002 | EP1179072A2 Combination neisserial compositions |
| 02/13/2002 | EP1179067A1 Neuroprotective properties of gdf-15, a novel member of the tgf-beta superfamily |